News
News
Tiziana Life Sciences to Proceed with Phase 2 Clinical Trial in Patients with Non-Active Secondary Progressive Multiple Sclerosis (SPMS)
Tiziana Life Sciences Ltd. (Nasdaq: TLSA) a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, today...
Read moreDetails
Splash Beverage Group’s Pulpoloco to be Available in Participating 7-Eleven and Speedway Stores
Splash Beverage Group, Inc. (NYSE American: SBEV) previously announced that Pulpoloco was awarded the 7-Eleven, Inc. Brands with Heart™ designation...
Read moreDetails
Brüush to Continue to Disrupt At-Home Oral Care with Upcoming New Products
After setting out to disrupt the oral care category with its sonic-powered electric toothbrush and brush head refill subscription plan,...
Read moreDetails
DSS Announces Letter to Shareholders
DSS, Inc. (“DSS” or the “Company”) (NYSE American: DSS), a multinational company operating nine business divisions through strategic acquisitions and...
Read moreDetails
Pressure BioSciences Announces the Exchange of Over $10 Million of Debt into Equity
Pressure BioSciences, Inc. announced that the Company’s largest shareholder has exchanged over $10 million of senior secured debt into unsecured...
Read moreDetails
SUNSHINE BIOPHARMA SIGNS EXCLUSIVE WORLDWIDE LICENSE WITH UNIVERSITY OF ARIZONA FOR PLpro-BASED COVID-19 TREATMENT
Sunshine Biopharma Inc. (NASDAQ: “SBFM”), a pharmaceutical company offering and researching life-saving medicines in a variety of therapeutic areas including...
Read moreDetails
OKYO Pharma Announces Custom Clearance of GMP Packaged OK-101 Drug to be Used in Phase 2 Clinical Trial for Treating Dry Eye Disease
OKYO Pharma Limited (LSE: OKYO; NASDAQ: OKYO), an ophthalmology-focused bio-pharmaceutical company which is developing OK-101 to treat dry eye disease...
Read moreDetails
OKYO Pharma Announces Appointment of Dr. Jay S. Pepose to its Scientific Advisory Board
OKYO Pharma Limited (LSE: OKYO, NASDAQ: OKYO), an ophthalmology-focused bio-pharmaceutical company developing OK-101 to treat dry eye disease (DED) to...
Read moreDetails
Mawson Infrastructure Group Inc Relocating 5,376 ASIC Miners to Pennsylvania Sites
Mawson Infrastructure Group Inc. (NASDAQ:MIGI) (“Mawson” or the “Company”), a digital infrastructure provider, announces today that it has closed its...
Read moreDetailsMawson Infrastructure Group Inc Expands Midland PA Facility by 100% to 100MW
Mawson Infrastructure Group Inc. (NASDAQ:MIGI) (“Mawson” or the “Company”), a digital infrastructure provider, announces today that it has installed 2...
Read moreDetails